Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Clinical Medicine (London, England)
|
July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK
Harry Knights, Nikhil Mayor, Kristina Millar, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 30, 2012
Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndrome
M Denise Robertson, John W Wright, Emmanuelle Loizon, et al.
Diabetes Technology & Therapeutics
|
July 31, 2025
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring-Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6
Thomas Danne, Susanne Engberg, Concetta Irace, et al.
Diabetes, Obesity & Metabolism
|
September 15, 2022
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes
Athena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 9, 2013
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 15, 2018
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis
Keith Bowering, Helena W Rodbard, David Russell-Jones, et al.
Lancet (London, England)
|
October 20, 2023
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
David Russell-Jones, Tetsuya Babazono, Roman Cailleteau, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 15, 2018
Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Martin B Whyte, Fariba Shojaee-Moradie, Sharaf E Sharaf, et al.
Diabetes Care
|
April 28, 2004
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial
Philip Home, Paul Bartley, David Russell-Jones, et al.
Diabetes Technology & Therapeutics
|
October 24, 2024
The Feasibility of an Experimental Hypobaric Simulation to Evaluate the Safety of Closed-Loop Insulin Delivery Systems in Flight-Related Atmospheric Pressure Changes
Ka Siu Fan, Fariba Shojaee-Moradie, Antonios Manoli, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Clinical Medicine (London, England)
|
July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK
Harry Knights, Nikhil Mayor, Kristina Millar, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 30, 2012
Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndrome
M Denise Robertson, John W Wright, Emmanuelle Loizon, et al.
Diabetes Technology & Therapeutics
|
July 31, 2025
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring-Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6
Thomas Danne, Susanne Engberg, Concetta Irace, et al.
Diabetes, Obesity & Metabolism
|
September 15, 2022
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes
Athena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 9, 2013
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 15, 2018
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis
Keith Bowering, Helena W Rodbard, David Russell-Jones, et al.
Lancet (London, England)
|
October 20, 2023
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
David Russell-Jones, Tetsuya Babazono, Roman Cailleteau, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 15, 2018
Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Martin B Whyte, Fariba Shojaee-Moradie, Sharaf E Sharaf, et al.
Diabetes Care
|
April 28, 2004
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial
Philip Home, Paul Bartley, David Russell-Jones, et al.
Diabetes Technology & Therapeutics
|
October 24, 2024
The Feasibility of an Experimental Hypobaric Simulation to Evaluate the Safety of Closed-Loop Insulin Delivery Systems in Flight-Related Atmospheric Pressure Changes
Ka Siu Fan, Fariba Shojaee-Moradie, Antonios Manoli, et al.
Page
of 6